Enveric Biosciences Inc. stock ripped 158.79 percent on Monday, April 20, 2026, after a new U.S. patent tied to its EVM301 series and lead neuroplastogen EB-003 lit a fire under the tiny biotech name. The Nasdaq-listed shares opened at $4.20, hit $5.43 and finished the day at $4.705 after closing at $1.82 on April 17.
The move was not a slow climb. A 5-minute chart showed aggressive premarket accumulation from around $1.90 to above $4.00 before regular trading even opened, then the stock held a regular-hours range between $4.10 and $5.43. For a company that had spent weeks grinding between roughly $1.75 and $2.10, the jump was abrupt and decisive.
The numbers behind the company help explain why traders pounced. Enveric reported about $4.68 million in cash, $5.10 million in total assets and $0.92 million in liabilities, giving it a current ratio above 5. It also posted about $2.19 million in quarterly net losses. That leaves the company with little room for error, but enough balance-sheet cushion for the market to treat any new intellectual-property win as material.
The real spark behind the surge was the patent covering a family of non-hallucinogenic neuroplastogenic molecules aimed at neuropsychiatric and addiction disorders. Enveric says the patent tightens its control over the EVM301 series and EB-003, the lead candidate it is developing for mental health disorders. The company is preparing an IND filing and a Phase 1 clinical trial for EB-003, and the new protection could give it more leverage in future partnerships or capital raises.
That matters because Enveric is still an early-stage, clinical-stage biotech that relies on external financing and cash raised via warrants. The patent is its main asset, which is why a single intellectual-property update was enough to send vgt stock traders chasing the name in a hurry. The tension now is whether the share move can outlast the catalyst: a stronger patent position does not erase the need for clinical progress, but it does sharpen the company’s hand as it heads toward its next regulatory steps.
For now, Monday’s trading showed exactly how fast a low-float biotech can reprice when a fresh catalyst lands. The patent gave Enveric a cleaner story, and the market answered before the session was even fully underway.
